Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Phase 2
1(14.3%)
7Total
Phase 1(6)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07557121Phase 2Not Yet Recruiting

Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

Role: lead

NCT05698329Phase 1Active Not Recruiting

Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

Role: lead

NCT04470726Phase 1Completed

Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype

Role: lead

NCT04827875Phase 1Completed

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

Role: lead

NCT04422899Phase 1Completed

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

Role: lead

NCT03639883Phase 1Completed

A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical Incision

Role: lead

NCT03883945Phase 1Withdrawn

A Safety and Efficacy Study to Evaluate Rosacea

Role: lead

All 7 trials loaded